Login to Your Account



PPD Pays $65M For Lilly's Patents For SSRI Sex Drug

By Randall Osborne


Monday, December 22, 2003
The contract research organization PPD Inc. is paying Eli Lilly and Co. $65 million in cash - about 37 percent of its available funds - for the patents related to dapoxetine, a selective serotonin reuptake inhibitor in late Phase III trials by Johnson & Johnson for premature ejaculation. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription